{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:38:24Z","timestamp":1783971504100,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic Arizona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clml.2024.09.002","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T15:55:34Z","timestamp":1726934134000},"page":"293-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["SOHO State of the Art Updates and Next Questions | Updates on Myelofibrosis With Cytopenia"],"prefix":"10.1016","volume":"25","author":[{"given":"Muhammad Ali","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2185-1504","authenticated-orcid":false,"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2024.09.002_bib0001","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2024.09.002_bib0002","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2024.09.002_bib0003","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.09.002_bib0004","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-022-01767-y","article-title":"Biological drivers of clinical phenotype in myelofibrosis","volume":"37","author":"Mascarenhas","year":"2023","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.clml.2024.09.002_bib0005","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.09.002_bib0006","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","article-title":"Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis","volume":"110","author":"Ciurea","year":"2007","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.clml.2024.09.002_bib0007","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","article-title":"Pathogenesis of myelofibrosis with myeloid metaplasia","volume":"23","author":"Tefferi","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.09.002_bib0008","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2141.1997.292671.x","article-title":"Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis","volume":"97","author":"Martyr\u00e9","year":"1997","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2024.09.002_bib0009","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1046\/j.1365-2141.1996.d01-1739.x","article-title":"Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation","volume":"93","author":"Dalley","year":"1996","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2012-02-402594","article-title":"Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection","volume":"120","author":"Papadantonakis","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.09.002_bib0011","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.23409","article-title":"The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms","volume":"88","author":"Tadmor","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2024.09.002_bib0012","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00428-013-1434-0","article-title":"Platelet derived growth factor receptor-beta (PDGFR\u03b2) expression is limited to activated stromal cells in the bone marrow and shows a strong correlation with the grade of myelofibrosis","volume":"463","author":"Bedekovics","year":"2013","journal-title":"Virchows Arch"},{"issue":"3","key":"10.1016\/j.clml.2024.09.002_bib0013","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2007.06807.x","article-title":"Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres","volume":"139","author":"Kuter","year":"2007","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2024.09.002_bib0014","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2214\/ajr.179.5.1791239","article-title":"Typical and atypical presentations of extramedullary hemopoiesis","volume":"179","author":"Georgiades","year":"2002","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"10.1016\/j.clml.2024.09.002_bib0015","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/1097-0142(19890415)63:8<1539::AID-CNCR2820630814>3.0.CO;2-5","article-title":"The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma","volume":"63","author":"O'Keane","year":"1989","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2024.09.002_bib0016","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1600-0609.1982.tb00611.x","article-title":"Assessment of bone marrow and splenic erythropoiesis in myelofibrosis","volume":"29","author":"Ferrant","year":"1982","journal-title":"Scand J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.09.002_bib0017","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.09.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106338","article-title":"Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported","volume":"91","author":"Masarova","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2024.09.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100715","article-title":"Current and future therapies for myelofibrosis","volume":"42","author":"Asher","year":"2020","journal-title":"Blood Rev"},{"issue":"7","key":"10.1016\/j.clml.2024.09.002_bib0020","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clml.2024.09.002_bib0021","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1200\/JCO.2019.37.15_suppl.7057","article-title":"Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): a reanalysis of the JAKARTA-2 study","volume":"37","author":"Harrison","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.09.002_bib0022","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1182\/blood-2022-156669","article-title":"Safety and efficacy of fedratinib in patients with primary (P), post-polycythemia vera (Post-PV), and post-essential thrombocythemia (Post-ET) myelofibrosis (MF) previously treated with ruxolitinib: primary analysis of the FREEDOM trial","volume":"140","author":"Gupta","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.09.002_bib0023","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2021-144505","article-title":"The impact of pacritinib on myelofibrosis symptoms in patients with moderate and severe thrombocytopenia: a retrospective analysis of patients in the persist-2 study","volume":"138","author":"Palmer","year":"2021","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2024.09.002_bib0024","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2019-129293","article-title":"Results of PAC203: a randomized phase 2 dose-finding study and determination of the recommended dose of pacritinib","volume":"134","author":"Gerds","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.002_bib0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-015-0021-2","article-title":"The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis","volume":"4","author":"McMullin","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"17","key":"10.1016\/j.clml.2024.09.002_bib0026","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.09.002_bib0027","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2141.2005.05524.x","article-title":"Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients","volume":"129","author":"Cervantes","year":"2005","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2024.09.002_bib0028","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","article-title":"Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results","volume":"94","author":"Cervantes","year":"2015","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.clml.2024.09.002_bib0029","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1517\/14656566.2011.568939","article-title":"Therapeutic approaches in myelofibrosis","volume":"12","author":"Barosi","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.clml.2024.09.002_bib0030","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","article-title":"Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial","volume":"22","author":"Marchetti","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.09.002_bib0031","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/cncr.21827","article-title":"Thalidomide therapy for myelofibrosis with myeloid metaplasia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clml.2024.09.002_bib0032","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","article-title":"Lenalidomide therapy in myelofibrosis with myeloid metaplasia","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.09.002_bib0033","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2016.300","article-title":"A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence","volume":"31","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.09.002_bib0034","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2001.02918.x","article-title":"Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia","volume":"114","author":"Barosi","year":"2001","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2024.09.002_bib0035","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.clml.2024.09.002_bib0036","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.09.002_bib0037","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/leu.2008.91","article-title":"A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia\/polycythemia vera myelofibrosis","volume":"22","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2024.09.002_bib0038","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199902113400601","article-title":"A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. transfusion requirements in critical care investigators, canadian critical care trials group","volume":"340","author":"H\u00e9bert","year":"1999","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2024.09.002_bib0039","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002042.pub2","article-title":"Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion","author":"Carless","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"10.1016\/j.clml.2024.09.002_bib0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cll.2021.07.005","article-title":"Platelet transfusion: an update on indications and guidelines","volume":"41","author":"Yuan","year":"2021","journal-title":"Clin Lab Med"},{"issue":"7","key":"10.1016\/j.clml.2024.09.002_bib0041","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ajh.23732","article-title":"A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers","volume":"89","author":"Attie","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2024.09.002_bib0042","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.clml.2024.09.002_bib0043","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2024.09.002_bib0044","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clml.2024.09.002_bib0045","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.clml.2024.09.002_bib0046","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: pelabresib in combination with ruxolitinib for janus kinase inhibitor treatment-na\u00efve myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.09.002_bib0047","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood-2023-181055","article-title":"ALK2 and JAK2 inhibition for improved treatment of anemia in myelofibrosis patients: preclinical profile of an ALK2 inhibitor zilurgisertib in combination with ruxolitinib","volume":"142","author":"Stubbs","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.09.002_bib0048","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.clml.2024.09.002_bib0049","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2024.09.002_bib0050","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic international prognostic scoring system (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.09.002_bib0051","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.09.002_bib0052","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.09.002_bib0053","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","article-title":"MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen","volume":"3","author":"Ali","year":"2019","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.clml.2024.09.002_bib0054","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2024.09.002_bib0055","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","article-title":"Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients","volume":"32","author":"Nicolosi","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.09.002_bib0056","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS","volume":"96","author":"Elena","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2024.09.002_bib0057","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2024.09.002_bib0058","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.09.002_bib0059","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.09.002_bib0060","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"34","key":"10.1016\/j.clml.2024.09.002_bib0061","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.09.002_bib0062","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.clml.2024.09.002_bib0063","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2217\/fon-2020-1048","article-title":"MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic","volume":"17","author":"Verstovsek","year":"2021","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.09.002_bib0064","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.clml.2024.09.002_bib0065","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024018160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024018160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:33:50Z","timestamp":1751398430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024018160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2152265024018160"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Updates on Myelofibrosis With Cytopenia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}